Nevisense system tests lesions before biopsy for melanoma

6th July 2017
Source: SciBase AB
Posted By : Enaie Azambuja
Nevisense system tests lesions before biopsy for melanoma

SciBase won FDA approval to introduce its Nevisense system to help dermatologists assess suspect cutaneous lesions that may be melanoma tumours. Unlike many technologies that have been attempted to characterise cancerous lesions, this one uses electrical impedance rather than optical methods. The system delivers electric current at different frequencies through the lesion using a pen-like device.

Melanoma tumour cells transmit electricity somewhat differently from normal healthy cells, and the effect of this can be detected using electrical impedance spectroscopy. Reference measurements taken in the past allow the system to compare with those and point to suspect melanoma during the exam.

The physician simply moistens the skin over the lesion, wipes off, and measures by placing the pen tip against the lesion. The table-top touchscreen display then provides a spectrogram of the readings and how out of normal range they are. Having this information dermatologists may then be able to form a better idea of whether to move toward biopsy of the suspect lesion.


You must be logged in to comment

Write a comment

No comments

Sign up to view our publications

Sign up

Sign up to view our downloads

Sign up

Med-Tech Innovation Expo 2018
25th April 2018
United Kingdom Ricoh Arena, Coventry